


- Amendments to the Claims -

Amend claims 1, 4, 12 and 25 as follows:

1. (Currently amended) A compound of Formula (1.0.0):



(1.0.0)

— wherein —

- j is 1;
- k is 0 or 1
- m is 1, 2, or 3;
- n is 1 or 2;
- W¹ and W² are independently —O— ; or —S(=O)_t— , where t is 0, 1, or 2;
- Y is =C(R¹_a)—, where R¹_a has the same meaning as defined below;

— where —

- R¹_a is a member selected from the group consisting of —H; —F; —Cl; —CN; —NO₂; —(C₁-C₄) alkyl; —(C₂-C₄) alkynyl; fluorinated-(C₁-C₃) alkyl; fluorinated-(C₁-C₃) alkoxy; —OR¹⁶; and —C(=O)NR²²_aR²²_b;

— where —

- R²²_a and R²²_b are each independently —H; —CH₃; —CH₂CH₃; —CH₂CH₂CH₃; —CH₂(CH₃)₂; —CH₂CH₂CH₂CH₃; —CH(CH₃)CH₂CH₃; —CH₂CH(CH₃)₂; —C(CH₃)₃; cyclopropyl; cyclobutyl; or cyclopentyl;

- Rᴬ and Rᴮ are each a member independently selected from the group consisting of —H; —F; —CF₃; —(C₁-C₄) alkyl; —(C₃-C₇) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R¹⁰;

— where —

- R¹⁰ is a member selected from the group consisting of phenyl; pyridyl; —F; —Cl; —CF₃; oxo (=O); —OR¹⁶; —NO₂; —CN; —C(=O)OR¹⁶; —O-C(=O)R¹⁶; —C(=O)NR¹⁶R¹⁷; —O-C(=O)NR¹⁶R¹⁷;

$-\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{16}\text{C}(=\text{O})\text{R}^{17}$; $-\text{NR}^{16}\text{C}(=\text{O})\text{OR}^{17}$; $-\text{NR}^{16}\text{S}(=\text{O})_2\text{R}^{17}$; and $-\text{S}(=\text{O})_2\text{NR}^{16}\text{R}^{17}$; where said phenyl or pyridyl is substituted by 0 to 3 R^{11} ;

— where —

$-\text{R}^{11}$ is $-\text{F}$; $-\text{Cl}$; $-\text{CF}_3$; $-\text{CN}$; $-\text{NO}_2$; $-\text{OH}$; $-(\text{C}_1-\text{C}_3)$ alkoxy; $-(\text{C}_1-\text{C}_3)$ alkyl; or $-\text{NR}^{16}\text{R}^{17}$;

— and —

$-\text{R}^{16}$ and R^{17} are each a member independently selected from the group consisting of $-\text{H}$; $-(\text{C}_1-\text{C}_4)$ alkyl; $-(\text{C}_2-\text{C}_4)$ alkenyl; $-(\text{C}_3-\text{C}_6)$ cycloalkyl; phenyl; benzyl; and pyridyl; wherein said alkyl, alkenyl, cycloalkyl, phenyl, benzyl, or pyridyl is substituted by 0 to 3 substituents selected from the group consisting of $-\text{F}$, $-\text{Cl}$, $-\text{CF}_3$, $-\text{CN}$, and $-(\text{C}_1-\text{C}_3)$ alkyl;

$-\text{R}^{\text{C}}$ and R^{D} have the same meaning as defined above for R^{A} and R^{B} except that one of them must be $-\text{H}$, and they are selected independently of each other and of R^{A} and R^{B} ;

$-\text{R}^1$ and R^2 may individually or together appear on any ring or rings comprising a meaning of the moiety J^2 as defined below; and R^1 and R^2 are each a member independently selected from the group consisting of $-\text{H}$; $-\text{F}$; $-\text{Cl}$; $-\text{CN}$; $-\text{NO}_2$; $-(\text{C}_1-\text{C}_4)$ alkyl; $-(\text{C}_2-\text{C}_4)$ alkynyl; fluorinated- $-(\text{C}_1-\text{C}_3)$ alkyl; $-\text{OR}^{16}$; and $-\text{C}(=\text{O})\text{NR}^{22}_{\text{a}}\text{R}^{22}_{\text{b}}$; where R^{16} , R^{22}_{a} , and R^{22}_{b} have the same meanings as defined above;

$-\text{R}^3$ is $-\text{H}$; $-(\text{C}_1-\text{C}_3)$ alkyl; phenyl; benzyl; or $-\text{OR}^{16}$, where R^{16} has the same meaning as defined above;

$-\text{R}^4$ may appear on any ring or rings comprising a meaning of the moiety J^1 as defined below; and R^4 are each a member independently selected from the group consisting of

— the following: —

-(a) $-\text{H}$; $-\text{F}$; $-\text{Cl}$; $-(\text{C}_2-\text{C}_4)$ alkynyl; $-\text{R}^{16}$; $-\text{OR}^{16}$; $-\text{S}(=\text{O})_p\text{R}^{16}$; $-\text{C}(=\text{O})\text{R}^{16}$; $-\text{C}(=\text{O})\text{OR}^{16}$; $-\text{OC}(=\text{O})\text{R}^{16}$; $-\text{CN}$; $-\text{NO}_2$; $-\text{C}(=\text{O})\text{NR}^{16}\text{R}^{17}$; $-\text{OC}(=\text{O})\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{22}_{\text{a}}\text{C}(=\text{O})\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{22}_{\text{a}}\text{C}(=\text{NR}^{12})\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{22}_{\text{a}}\text{C}(=\text{NCN})\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{22}_{\text{a}}\text{C}(=\text{N-NO}_2)\text{NR}^{16}\text{R}^{17}$; $-\text{C}(=\text{NR}^{22}_{\text{a}})\text{NR}^{16}\text{R}^{17}$; $-\text{CH}_2\text{C}(=\text{NR}^{22}_{\text{a}})\text{NR}^{16}\text{R}^{17}$; $-\text{OC}(=\text{NR}^{22}_{\text{a}})\text{NR}^{16}\text{R}^{17}$; $-\text{OC}(=\text{N-NO}_2)\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{16}\text{R}^{17}$; $-\text{CH}_2\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{22}_{\text{a}}\text{C}(=\text{O})\text{R}^{16}$; $-\text{NR}^{22}_{\text{a}}\text{C}(=\text{O})\text{OR}^{16}$; $=\text{NOR}^{16}$; $-\text{NR}^{22}_{\text{a}}\text{S}(=\text{O})_p\text{R}^{17}$; $-\text{S}(=\text{O})_p\text{NR}^{16}\text{R}^{17}$; and $-\text{CH}_2\text{C}(=\text{NR}^{22}_{\text{a}})\text{NR}^{16}\text{R}^{17}$;

— where —

$-\text{p}$ is 0, 1, or 2; and R^{22}_{a} , R^{16} , and R^{17} have the same meanings as defined above;

-(b) $-(\text{C}_1-\text{C}_4)$ alkyl; and $-(\text{C}_1-\text{C}_4)$ alkoxy in the case where R^4 has the meaning of $-\text{OR}^{16}$ under (a) above and R^{16} is defined as $-(\text{C}_1-\text{C}_4)$ alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents $-\text{F}$ or $-\text{Cl}$; or 0 or 1 substituent (C_1-C_2) alkoxycarbonyl-; (C_1-C_2) alkylcarbonyl-; or (C_1-C_2) alkylcarbonyloxy-; provided R^{16} and R^{17} in the definition of R^4 is not pyridyl;

--R¹⁴ is a member selected from the group consisting of -(C₁-C₄) alkyl; -(C₃-C₇) cycloalkyl; phenyl; benzyl; where said alkyl, cycloalkyl, phenyl and benzyl are substituted by 0, 1, or 2 substituents -F, -Cl, -CH₃, -OR¹⁶, -NO₂, -CN, or -NR¹⁶R¹⁷; and said R¹⁴ group further consists of -F; -Cl; -CF₃; oxo (=O); -OR¹⁶; -NO₂; -CN; -C(=O)OR¹⁶; -O-C(=O)R¹⁶; -C(=O)NR¹⁶R¹⁷; -O-C(=O)NR¹⁶R¹⁷; -NR¹⁶R¹⁷; -NR¹⁶C(=O)R¹⁷; -NR¹⁶C(=O)OR¹⁷; -NR¹⁶S(=O)₂R¹⁷; or -S(=O)₂NR¹⁶R¹⁷; where R¹⁶ and R¹⁷ have the same meanings as defined above; provided that said R¹⁶ and R¹⁷ in the definition of R¹⁴ is not pyridyl;


----R¹² is a member independently selected from the group consisting of -F; -Cl; -CO₂R¹⁸; -OR¹⁶; -CN; -C(=O)NR¹⁸R¹⁹; -NR¹⁸R¹⁹; -NR¹⁸C(=O)R¹⁹; -NR¹⁸C(=O)OR¹⁹; -NR¹⁸S(=O)_pR¹⁹; -S(=O)_pNR¹⁸R¹⁹, where p is 1 or 2; -(C₁-C₄) alkyl; and -(C₁-C₄) alkoxy in the case where R¹² has the meaning of -OR¹⁶ above and R¹⁶ is defined as -(C₁-C₄) alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents independently selected from -F; -Cl; -(C₁-C₂) alkoxycarbonyl; -(C₁-C₂) alkylcarbonyl; and -(C₁-C₂) alkylcarbonyloxy; where R¹⁶ has the same meaning as defined above; and

— where —


-----R¹⁸ and R¹⁹ are independently selected from the group consisting of -H; -(C₁-C₄) alkyl; and phenyl; where said alkyl or phenyl is substituted by 0-3 of -F; or -Cl;

— or in the case where J¹ is phenyl —


-(d) R⁵ and R⁶ are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1) through (1.3.3) and (1.3.5) through (1.3.15):




(1.3.1)




(1.3.2)




(1.3.3)




(1.3.5)




(1.3.6)




(1.3.7)




(1.3.8)




(1.3.9)




(1.3.10)




(1.3.11)




(1.3.12)



(1.3.13)



(1.3.14)



(1.3.15)

— wherein —

--R²⁰ and R²¹ are each a member independently selected from the group consisting of
 -H; -F; -Cl; -CH₃; -CH₂F; -CHF₂; -CF₃; -OCH₃; and -OCF₃;

--R²³ and R²⁴ are each independently -H; -CH₃; -OCH₃; -CH₂CH₃; -OCH₂CH₃;
 -CH₂CH₂CH₃; -CH₂(CH₃)₂; -CH₂CH₂CH₂CH₃; -CH(CH₃)CH₂CH₃; -CH₂CH(CH₃)₂; -C(CH₃)₃; or
 absent, in which case the dashed line ---- represents a double bond;


-J¹ is a moiety comprising an a-saturated or unsaturated carbon ring system that is
 a 6-membered monocyclic ring;

-J² is a moiety comprising an a-saturated or unsaturated carbon ring system that is
 a 6-membered monocyclic ring;


-D is a member independently selected from the group consisting of

— the following —


-(a) the group consisting of partial Formulas (1.1.1) through (1.1.5):




(1.1.1)




(1.1.2)



(1.1.3)



(1.1.4)



(1.1.5)

— wherein —

--“*” indicates the point of attachment of each partial Formula (1.1.1) through (1.1.5)
 to the remaining portion of Formula (1.0.0);

--q is 1, 2, or 3, provided that where q is 2 or 3, R⁹ has the meaning of -H in at least
 one instance, or two instances, respectively;

--v 0 or 1;

--W³ is -O-; -N(R⁹)-, where R⁹ has the same meaning as defined below; or -
 OC(=O)-;

--R⁷ is a member independently selected from the group consisting of

— the following: —

--(1) ————H;

--(2) (1) —(C₁-C₆) alkyl; —(C₂-C₆) alkenyl; or —(C₂-C₆) alkynyl; where said alkyl, alkenyl or alkynyl is substituted by 0 to 3 substituents R¹⁰, where R¹⁰ has the same meaning as defined above; provided that R¹⁰ in the meaning of R⁷ --(2) is not pyridyl;

--(3) (2) —(CH₂)_u-(C₃-C₇) cycloalkyl where u is 0, 1 or 2; and further where said (C₃-C₇) cycloalkyl is substituted by 0 to 3 substituents R¹⁰ where R¹⁰ has the same meaning as defined above; provided that R¹⁰ in the meaning of R⁷ --(3) is not pyridyl;

— and —

--(4) (3) phenyl or benzyl, where said phenyl or benzyl is independently substituted by 0 to 3 substituents R¹⁰ where R¹⁰ has the same meaning as defined above; provided that R¹⁰ in the meaning of R⁷ --(4) is not pyridyl;

--R⁸ is phenyl;

— where —

said phenyl is optionally substituent R¹⁴;

--R⁹ is a member selected from the group consisting of —H; —(C₁-C₄) alkyl; —(C₃-C₇) cycloalkyl; phenyl; benzyl; —C(=O)OR¹⁶; —C(=O)R¹⁶; —OR¹⁶; —(C₁-C₂) alkyl-OR¹⁶; and —(C₁-C₂) alkyl-C(=O)OR¹⁶; provided that R¹⁶ in the definition of R⁹ is not pyridyl;

— and D is further selected from —

-(b) a moiety comprising a member selected from the group consisting of —O-P(=O)(OH)₂ (phosphoric); —PH(=O)OH (phosphinic); —P(=O)(OH)₂ (phosphonic); —[P(=O)(OH)—O(C₁-C₄) alkyl] (alkylphosphono); —P(=O)(OH)—O(C₁-C₄) alkyl (alkylphosphinyl); —P(=O)(OH)NH₂ (phosphoramido); —P(=O)(OH)NH(C₁-C₄) alkyl and —P(=O)(OH)NHR²⁵ (substituted phosphoramido); —O-S(=O)₂OH (sulfuric); —S(=O)₂OH (sulfonic); —S(=O)₂NHR²⁶ or —NHS(=O)₂R²⁶ (sulfonamido) where R²⁶ is —CH₃, —CF₃, or o-toluy; and acylsulfonamido selected from the group consisting of —C(=O)NHS(=O)₂R²⁵; —C(=O)NHS(=O)₂NH₂; —C(=O)NHS(=O)₂(C₁-C₄) alkyl; —C(=O)NHS(=O)₂NH(C₁-C₄) alkyl; —C(=O)NHS(=O)₂N[(C₁-C₄) alkyl]₂; —S(=O)₂NHC(=O)(C₁-C₄) alkyl; —S(=O)₂NHC(=O)NH₂; —S(=O)₂NHC(=O)NH(C₁-C₄) alkyl; —S(=O)₂NHC(=O)N[(C₁-C₄) alkyl]₂; —S(=O)₂NHC(=O)R²⁵; —S(=O)₂NHCN; —S(=O)₂NHC(=S)NH₂; —S(=O)₂NHC(=S)NH(C₁-C₄) alkyl; —S(=O)₂NHC(=S)N[(C₁-C₄) alkyl]₂; and —S(=O)₂NHS(=O)₂R²⁵;

— where —

--R²⁵ is —H; —(C₁-C₄) alkyl; phenyl; or —OR¹⁸, where R¹⁸ has the same meaning as defined above;


— or —

a pharmaceutically acceptable salt thereof.

2. (Canceled)


3. (Canceled)

4. (Currently amended) A compound according to Claim 1 wherein the right-hand terminus thereof, where m is 1, is represented by partial Formula (1.0.5):




(1.0.5)


where “*” is a symbol representing the point of attachment of the moiety of partial Formula (1.0.5) to the remaining portion of a compound of Formula (1.0.0); where R^A and R^B are both -H, or one is -H and the other is -CH₃, or both are -CH₃; R^1 is -H, -OCH₃, or 2'-F; R^2 is -H; and the moieties J^2 and D are selected such that, said moiety of partial Formula (1.0.5) is a member selected from the group consisting of partial Formulas (1.5.1), (1.5.3), (1.5.5) through (1.5.8), (1.5.10) through (1.5.12), (1.5.18), (1.5.19), 1.5.21 and (1.5.47 through (1.5.22), (1.5.26), (1.5.27) and (1.5.32):




(1.5.1)




(1.5.3)




(1.5.5)




(1.5.6)




(1.5.7)




(1.5.8)




(1.5.10)



(1.5.11)



(1.5.12)




– wherein –

“*” indicates the point of attachment of each said group of partial Formula (1.0.5) represented by partial Formulas (1.5.1), (1.5.3), (1.5.5) through (1.5.8), (1.5.10) through (1.5.12), (1.5.18), (1.5.19), (1.5.21) and (1.5.22) (1.5.17 through (1.5.24), (1.5.26), (1.5.27 and (1.5.32) to the remaining portion of Formula (1.0.0).


5. (Canceled)

6. (Canceled)


7. (Previously presented) A compound according to Claim 1 wherein J' and the substituents R⁴, R⁵, and R⁶ are selected in such a way that a portion of the left-hand terminus of a compound of Claim 1 is a member selected from the group consisting of partial Formulas (2.0.11), (2.0.12), (2.0.14) - (2.0.20), (2.0.40), (2.0.60), (2.0.63) and (2.0.66) - (2.0.70):




(2.0.11)




(2.0.12)




(2.0.14)




(2.0.15)




(2.0.16)




(2.0.17)




(2.0.18)




(2.0.19)




(2.0.20)



(2.0.40)





(2.0.63)




8. (Canceled)

9. (Currently amended) A compound according to Claim 1 wherein J^2 and the substituents R^1 and R^2 are selected in such a way that a portion of the right-hand terminus of a compound of Claim 1 is a member selected from the group consisting of partial Formulas (2.5.1) to (2.5.7), (2.5.10), (2.5.14), (2.5.24) to (2.5.26), (2.5.34), (2.5.37 to (2.5.41) and (2.5.50):







(2.5.24)




(2.5.25)




(2.5.26)




(2.5.34)




(2.5.37)




(2.5.38)




(2.5.39)



(2.5.40)



(2.5.41)



(2.5.50)

10. (Original) A compound according to Claim 1 wherein Y is $\text{=C(R}^1_a\text{)}\text{—}$ where R^1_a is —H ; —F ; —Cl ; —CH_3 ; or —OCH_3 .

11. (Original) A compound according to Claim 10 wherein R^1_a is —H ; or —F .

12. (Currently amended) A compound according to Claim 1 wherein where m is 1 or 2, and n is 1; ♦ R^A and R^B are —H , —CF_3 , or $\text{—(C}_1\text{—C}_6\text{) alkyl}$ substituted by 0 or 1 of —F , —Cl , —CF_3 , —CN , —NH_2 , or —C(=O)NH_2 ; ♦ one of R^C and R^D is —H , and the other is —H , $\text{—(C}_1\text{—C}_4\text{) alkyl}$, or

phenyl, each substituted by 0 or 1 of -F, -Cl, or -CN; ♦ W¹ is -O- or -S-; ♦ W² is -O-; ♦ Y is =C(R¹_a)— where R¹_a is -H, -F, -Cl, -CN, -CH₃, or -OCH₃; ♦ R¹ and R² are -H, -F, -Cl, -CN, -NO₂, -OH, -CH₃, -OCH₃, -OCHF₂, or -OCF₃; ♦ R³ is -H or -CH₃; ♦ R⁴ is -H, -F, -CN, -NO₂, -OH, -CH₃, or -OCH₃; ♦ J¹ is phenyl; ♦ R⁵ and R⁶ are taken together to form a moiety of partial Formula (1.3.1) where R²⁰ and R²¹ are -H or -CH₃; or a moiety of partial Formula (1.3.11), (1.3.12), or (1.3.15) where R²³ and R²⁴ are absent or are -H, or -CH₃; ♦ J² is phenyl, norbornanyl or cyclohexyl; ♦ and D is -C(=O)OR⁷ where R⁷ is -H or -CH₃; or -C(=O)NH₂.

13. (Currently amended) A compound according to Claim 12 wherein R^A and R^B are both -CH₃, or one is -CH₃ and the other is -CH(CH₃)₂ or -C(CH₃)₃, or one is -H and the other is -CH₃ or -CF₃; ♦ one of R^C and R^D is -H and the other is -H or -CH₃; W¹ is -O-; ♦ Y is =C(R¹_a)— where R¹_a is -H, -F, or -Cl; ♦ R¹ and R² are -H, -F, or Cl; ♦ R³ is -H; ♦ R⁴ is -H; ♦ R⁵ and R⁶ are taken together to form a moiety of partial Formula (1.3.1) or (1.3.11) where R²³ and R²⁴ are both absent; ♦ J² is phenyl or cyclohexyl; ♦ and D is -C(=O)OR⁷ where R⁷ is -H, -CH₃ or -C(=O)NH₂.

14. (Currently amended) A compound according to Claim 13 wherein R^A and R^B are both -CH₃; ♦ one of R^C and R^D is -H and the other is -H or -CH₃; ♦ Y is =C(R¹_a)— where R¹_a is -H, -F, or -Cl; ♦ R¹ and R² are -H, -F, or Cl; ♦ R³ is -H; ♦ R⁴ is -H; ♦ R⁵ and R⁶ are taken together to form a moiety of partial Formula (1.3.11) where R²³ and R²⁴ are both absent; ♦ J² is phenyl; ♦ and D is -C(=O)OR⁷ where R⁷ is -H or -CH₃ or -C(=O)NH₂.

15. (Original) A compound according to Claim 14 wherein R^A and R^B are both -CH₃; ♦ R^C and R^D are both -H; ♦ Y is =C(R¹_a)— where R¹_a is -H; ♦ and one of R¹ and R² is -H and the other is -F.

16. (Original) A compound according to Claim 14 wherein Y is =C(R¹_a)— where R¹_a is -F; ♦ and R¹ and R² are both -H.


17. (Currently amended) A compound according to Claim 13 wherein R^A and R^B are both -CH₃; ♦ one of R^C and R^D is -H and the other is -H or -CH₃; ♦ Y is =C(R¹_a)— where R¹_a is -H, -F, or -Cl; ♦ R¹ and R² are -H, -F, or Cl; ♦ R³ is -H; ♦ R⁴ is -H; R⁵ and R⁶ are taken together to form a moiety of partial Formula (1.3.1) where R²⁰ and R²¹ are both -H; ♦ J² is phenyl; ♦ and D is -C(=O)OR⁷ where R⁷ is -H or -CH₃ or -C(=O)NH₂.

18. (Original) A compound according to Claim 17 wherein R^A and R^B are both $-\text{CH}_3$; \blacklozenge R^C and R^D are both $-\text{H}$; \blacklozenge Y is $=\text{C}(R^1_a)-$ where R^1_a is $-\text{H}$; \blacklozenge and one of R^1 and R^2 is $-\text{H}$ and the other is $-\text{F}$.


19. (Original) A compound according to Claim 18 wherein Y is $=\text{C}(R^1_a)-$ where R^1_a is $-\text{F}$; \blacklozenge and R^1 and R^2 are both $-\text{H}$.

20. (Previously presented) A compound according to Claim 1 wherein D is $-\text{P}(=\text{O})(\text{OH})\text{NHR}^{25}$; $-\text{S}(=\text{O})_2\text{NHR}^{26}$ or $-\text{NHS}(=\text{O})_2\text{R}^{26}$ where R^{26} is $-\text{CH}_3$, $-\text{CF}_3$, or o -toluyl; or $-\text{C}(=\text{O})\text{NHS}(=\text{O})_2\text{R}^{25}$.


21. (Previously presented) A compound according to Claim 1 wherein R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1), (1.3.11), (1.3.12), and (1.3.15):




(1.3.1)



(1.3.11)




(1.3.12)




(1.3.15).


22. (Original) A compound according to Claim 21 wherein R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (2.1.1), (2.1.4) through (2.1.6), (2.1.11), and (2.1.16) through (2.1.20):




(2.1.1)




(2.1.4)




(2.1.5)




(2.1.6)




(2.1.11)




(2.1.16)




(2.1.17)



(2.1.18)



(2.1.19)



(2.1.20)

wherein the dashed line $----$ in partial Formulas (2.1.18), (2.1.19), and (2.1.20) represents a double bond where no oxygen atom is attached to the corresponding nitrogen atom, and

represents a single bond where an oxygen atom is attached to said corresponding nitrogen atom.

23. (Previously presented) A compound according to Claim 1 wherein the J² moiety is cyclohexenyl.

24. (Canceled)

25. (Currently amended) ~~A compound according to Claim 1 wherein said compound is a member selected from the group consisting of the following:~~

~~[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-acetic acid;~~

~~(±)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid;~~

~~(±)-2-[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;~~

~~(±)-2-[3-Fluoro-4-({[2-(3-cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid~~ (±)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid;

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid;

(S)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid;

(R)-2-[3-Fluoro-4-({[2-(3-cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid;

(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-nicotinamide;

(R)-N-[4-(1-Carbamoyl-ethoxy)-2-fluoro-benzyl]-2-(3-cyano-phenoxy)-nicotinamide;

(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-5-fluoro-nicotinamide;

~~[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid;~~

(±)-2-[4-(((2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohex-3-enyloxy]-propionic acid;

(±)-2-[4-(((2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohex-3-enyloxy]-propionic acid;

(±)-2-[4-(((2-(3-Cyano-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohex-3-enyloxy]-propionic acid;

(R)-2-[4-(((2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohex-3-enyloxy]-propionic acid;

(R)-2-[4-(((2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohex-3-enyloxy]-propionic acid;

(R)-2-[4-(((2-(3-Cyano-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohex-3-enyloxy]-propionic acid;

4-(((2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-acetic acid;

4-(((2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-acetic acid;

4-(((2-(3-Cyano-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-acetic acid;

(±)-2-[4-(((2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-propionic acid;

(±)-2-[4-(((2-(3-Cyano-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-propionic acid;

(R)-2-[4-(((2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-propionic acid;

(R)-2-[4-(((2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-propionic acid;

(R)-2-[4-(((2-(3-Cyano-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-propionic acid;

2-[4-(((2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-2-methyl-propionic acid;

2-[4-(((2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-2-methyl-propionic acid;

2-[4-(((2-(3-Cyano-phenoxy)-pyridine-3-carbonyl)-amino)-methyl)-cyclohexyloxy]-2-methyl-propionic acid;

2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid;

2-[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-2-methyl-propionic acid;

2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid;

(±)-2-[3-Fluoro-4-({[2-(3-nitro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;

~~[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid;~~

~~[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid;~~

(R)-2-[4-({[2-(3-Methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;

(R)-2-[3-Fluoro-4-({[2-(3-methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;

(R)-2-[3-Fluoro-4-({[5-fluoro-2-(3-methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;

(R)-2-[4-({[2-(3-Nitro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;

(R)-2-[4-({[2-(3-Chloro-4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;

(R)-2-[4-({[2-(3,4-Difluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid;

(R)-2-[4-({[2-(2,3-Dihydro-benzofuran-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid; ~~and~~ or

(R)-2-[4-({[2-(2,3-Dihydro-benzofuran-6-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid.

26. - 30. (Canceled)

31. (Currently amended) A method of treating a respiratory disease, disorder or condition mediated by the PDE4 isozyme in a mammal, said method comprising administering to said mammal in need of such mediation, a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

32. (Previously presented) A method of claim 31 wherein said PDE4 isozyme is the PDE4-D subtype isozyme.

33. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is atopic asthma; non-atopic asthma; allergic asthma; bronchial asthma; essential asthma; true asthma; intrinsic asthma caused by pathophysiologic disturbances; extrinsic asthma caused by environmental factors; essential asthma of unknown or inapparent cause; bronchitic asthma; emphysematous asthma; exercise-induced asthma; occupational asthma; infective asthma caused by bacterial, fungal, protozoal or viral infection; non-allergic asthma; incipient asthma; or wheezy infant syndrome.

34. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is chronic or acute bronchoconstriction; chronic bronchitis; small airways obstruction; emphysema; pneumoconiosis; chronic eosinophilic pneumonia; chronic obstructive pulmonary disease; adult respiratory distress syndrome; or exacerbation of airways hyper-reactivity consequent to other drug therapy.

35. (Previously presented) A method of claim 34 wherein said chronic obstructive pulmonary disease is characterized by irreversible, progressive airways obstruction.

36. (Previously presented) A method of claim 34 wherein said pneumoconiosis is aluminosis; bauxite workers' disease; anthracosis; miners' disease; asbestosis; steam-fitters' asthma; chalicosis; flint disease; ptilosis caused by inhaling the dust from ostrich feathers; siderosis caused by the inhalation of iron particles; silicosis; grinders' disease; byssinosis; cotton-dust asthma; or talc pneumoconiosis.

37. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is bronchitis; acute bronchitis; chronic bronchitis; acute laryngotracheal bronchitis; arachidic bronchitis; catarrhal bronchitis; croupus bronchitis; dry bronchitis; infectious asthmatic bronchitis; productive bronchitis; staphylococcus bronchitis; streptococcal bronchitis; or vesicular bronchitis.

38. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is bronchiectasis; cylindric bronchiectasis; sacculated bronchiectasis; fusiform bronchiectasis; capillary bronchiectasis; cystic bronchiectasis; dry bronchiectasis or follicular bronchiectasis.

39. (Previously presented) A method of claim 31 wherein said disease, disorder or condition is seasonal allergic rhinitis; perennial allergic rhinitis; sinusitis; purulent sinusitis; nonpurulent sinusitis; acute sinusitis; chronic sinusitis; ethmoid sinusitis; frontal sinusitis; or sphenoid sinusitis.

40. (Canceled)

41. (Currently amended) A compound of claim 1 which is (R)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino)-methyl]-3-fluoro-phenoxy]-propionic acid.

42. (New) A method of treating a respiratory disease, disorder or condition mediated by the PDE4 isozyme in a mammal, said method comprising administering to said mammal in need of such mediation, a therapeutically effective amount of a compound of Claim 41 or a pharmaceutically acceptable salt thereof.

43. (New) A method of claim 42 wherein said PDE4 isozyme is the PDE4-D subtype isozyme.

44. (New) A method of claim 42 wherein said disease, disorder or condition is atopic asthma; non-atopic asthma; allergic asthma; bronchial asthma; essential asthma; true asthma; intrinsic asthma caused by pathophysiologic disturbances; extrinsic asthma caused by environmental factors; essential asthma of unknown or inapparent cause; bronchitic asthma; emphysematous asthma; exercise-induced asthma; occupational asthma; infective asthma caused by bacterial, fungal, protozoal or viral infection; non-allergic asthma; incipient asthma; or wheezy infant syndrome.

45. (New) A method of claim 42 wherein said disease, disorder or condition is chronic or acute bronchoconstriction; chronic bronchitis; small airways obstruction; emphysema; pneumoconiosis; chronic eosinophilic pneumonia; chronic obstructive pulmonary disease; adult respiratory distress syndrome; or exacerbation of airways hyper-reactivity consequent to other drug therapy.

46. (New) A method of claim 45 wherein said chronic obstructive pulmonary disease is characterized by irreversible, progressive airways obstruction.

47. (New) A method of claim 45 wherein said pneumoconiosis is aluminosis; bauxite workers' disease; anthracosis; miners' disease; asbestosis; steam-fitters' asthma; chalicosis; flint disease; ptilosis caused by inhaling the dust from ostrich feathers; siderosis caused by the inhalation of iron particles; silicosis; grinders' disease; byssinosis; cotton-dust asthma; or talc pneumoconiosis.

48. (New) A method of claim 42 wherein said disease, disorder or condition is bronchitis; acute bronchitis; chronic bronchitis; acute laryngotracheal bronchitis; arachidic bronchitis; catarrhal bronchitis; croupus bronchitis; dry bronchitis; infectious asthmatic bronchitis; productive bronchitis; staphylococcus bronchitis; streptococcal bronchitis; or vesicular bronchitis.

49. (New) A method of claim 42 wherein said disease, disorder or condition is bronchiectasis; cylindric bronchiectasis; sacculated bronchiectasis; fusiform bronchiectasis; capillary bronchiectasis; cystic bronchiectasis; dry bronchiectasis or follicular bronchiectasis.

50. (New) A method of claim 42 wherein said disease, disorder or condition is seasonal allergic rhinitis; perennial allergic rhinitis; sinusitis; purulent sinusitis; nonpurulent sinusitis; acute sinusitis; chronic sinusitis; ethmoid sinusitis; frontal sinusitis; or sphenoid sinusitis.

51. (New) A pharmaceutical composition comprising a compound of claim 41 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.